Company Description
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada.
It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension.
The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.
Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
| Country | United States |
| IPO Date | Apr 4, 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Christopher T. Giordano |
Contact Details
Address: ONE Copley Parkway Morrisville, North Carolina United States | |
| Website | https://www.tenaxthera.com |
Stock Details
| Ticker Symbol | TENX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000034956 |
| CUSIP Number | 88032L209 |
| ISIN Number | US88032L6056 |
| Employer ID | 26-2593535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher T. Giordano | Chief Executive Officer, President & Director |
| Lawrence R. Hoffman CPA, Esq. | Interim Chief Financial Officer |
| Doug Randall | Executive Vice President of Commercial & Business Operations |
| Dr. Douglas Hay | Senior Vice President of Regulatory Affairs |
| Dr. Stuart Rich M.D. | Chief Medical Officer & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 4 | Filing |
| Dec 12, 2024 | 4 | Filing |
| Dec 12, 2024 | 4 | Filing |
| Dec 12, 2024 | 4 | Filing |
| Dec 12, 2024 | 4 | Filing |
| Dec 12, 2024 | 4 | Filing |
| Dec 12, 2024 | 4 | Filing |
| Dec 06, 2024 | 3 | Filing |
| Dec 05, 2024 | SCHEDULE 13G | Filing |
| Dec 04, 2024 | 8-K | Current Report |